Updated on 24 June 2014
The rise in private funding has paved the way for innovations in the Indonesia's infectious disease IVD market
Singapore: Infectious disease market is one of the largest segments of in-vitro diagnostics (IVD) market in Indonesia, accounting for approximately 62 percent of the total market marking revenue of $38.6 million in 2013, according to a report by Frost & Sullivan.
The market is expected to reach $59.9 million by 2017. The report states that the increased incidence of infectious diseases such as hepatitis C, HIV, TB, malaria and dengue have spurred the government to invest strongly in primary healthcare system, public hospital reforms, promotion of IVD-related technology innovation among local participants, and improved reimbursement policy, thus creating a favorable climate for market participants.
The market is segmented into immunochemistry testing, microbiology testing, and molecular diagnostics testing. Among these, the molecular diagnostics segment, which includes virology, bacteriology, molecular blood donor screening and genetic testing, is expected to grow the fastest.
Frost and Sullivan mentions that despite the strong government backing, Indonesia's infectious disease IVD market is battling a shortage of skilled healthcare workers and laboratory facilities. This issue hampers the accurate identification, diagnosis and reporting of infectious diseases in the country.
The market is further pegged back by the long turnaround times of tests and high level of investments needed. These challenges, however, are opportunities for companies in the opposite ends of the spectrum.